Boehringer Ingelheim Pharmaceuticals, Inc. has announced encouraging results from a real-world analysis showing that Pradaxa (dabigatran etexilate mesylate) was associated with an improvement in safety and efficacy outcomes compared to warfarin in patients with non-valvular atrial fibrillation (NVAF).
The results were presented at the International Stroke Conference. The study analyzed 7,245 PRADAXA and 14,490 warfarin patients with NVAF who had no prior use of an oral anticoagulant (OAC),
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox